The Patent Finder
IM

ImmunoGen, Inc.

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

118 patents currently held

4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
22 more records may belong here and await a decision; they are not counted.

The next term ends in Mar 2027. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
25
Ending by 2030
Mar 2027
Next term end
45
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Method of Targeting Specific Cell Populations Using Cell-Binding Agent Maytansinoid Conjugates Linked via a Non-Cleavable Linker, Said Conjugates, and Methods of Making Said Conjugates US 8,088,387
The most cited patent in this portfolio, cited by 260 later US patents, top 5% of utility patents granted in 2012 in our data. Protection runs to 2028.
Ends Jul 2028 · High confidence
Also notable
Cross-Linkers and Their Uses US 8,236,319
Cited by 186 later US patents, top 5% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030.
Ends Jul 2030 · High confidence
Also notable
Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof US 8,557,966
Cited by 74 later US patents, top 10% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.
Ends Feb 2031 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 23, 2026
    The maintenance fee for Cross-Linkers and Their Uses (US 9,061,995) comes due Dec 23, 2026. Unpaid by Jun 23, 2027, it lapses early.
  • 1 fee due Jan 18, 2027
    The maintenance fee for Therapeutic Combinations Comprising ANTI-CD123 Immunoconjugates (US 11,701,428) comes due Jan 18, 2027. Unpaid by Jul 19, 2027, it lapses early.
  • 3 fees due Feb 6 to 22, 2027 · next Feb 6
  • 3 fees due Mar 5 to 19, 2027 · next Mar 5
  • 7 fees due Apr 8 to 29, 2027 · next Apr 8
  • 1 fee due May 3, 2027
    The maintenance fee for CD20 Antibodies and Uses Thereof (US 9,175,086) comes due May 3, 2027. Unpaid by Nov 3, 2027, it lapses early.
  • 5 fees due Jun 1 to 5, 2027 · next Jun 1
  • 2 fees due Jul 26 to 28, 2027 · next Jul 26
  • 2 fees due Aug 13 to 23, 2027 · next Aug 13
  • 1 fee due Sep 19, 2027
    The maintenance fee for Method for Increasing the Efficacy of Cancer Therapy by Administering an ANTI-FOLR1 Immunoconjugate (US 11,932,701) comes due Sep 19, 2027. Unpaid by Mar 20, 2028, it lapses early.
  • 2 fees due Oct 2 to 7, 2027 · next Oct 2
  • 2 fees due Nov 14, 2027

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 23, 2026
  • 2 terms have ended since Aug 23, 2026

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 8,499,893Oil Scavenge System Having Churning Damper for Gas Turbine Engines
In force
 · Medium confidence
In forceMedium confidence
US 7,811,572Process for Preparing Purified Drug Conjugates
In force
 · Medium confidence
In forceMedium confidence
US 7,989,598Method of Targeting Specific Cell Populations Using Cell-Binding Agent Maytansinoid Conjugates Linked via a Non-Cleavable Linker, Said Conjugates and Methods of Making Said Conjugates
In force
 · High confidence
In forceHigh confidence
US 8,088,387Method of Targeting Specific Cell Populations Using Cell-Binding Agent Maytansinoid Conjugates Linked via a Non-Cleavable Linker, Said Conjugates, and Methods of Making Said Conjugates
In force
 · High confidence
In forceHigh confidence
US 8,119,813Method for Preparing Enantiomerically Enriched N-Carboxyanhydride
In force
 · High confidence
In forceHigh confidence
US 8,613,930Cross-Linkers and Their Uses
In force
 · High confidence
In forceHigh confidence
US 9,061,995Cross-Linkers and Their Uses
In force
 · Medium confidence
In forceMedium confidence
US 9,498,541Cross-Linkers and Their Uses
In force
 · Medium confidence
In forceMedium confidence
US 10,494,431Cross-Linkers and Their Uses
In force
 · Medium confidence
In forceMedium confidence
US 11,046,762Cross-Linkers and Their Uses
In force
 · Medium confidence
In forceMedium confidence
10 of 118 patents shown.
Pro members see all 118.
Pro members: see all 118 patents
Also on record, not counted in the 118: 4 patents in force now held by others · 95 patents ended · 26 applications pending · 125 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited